Timothy M. Kuzel

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

Robert J. Motzer, Brian I. Rini, David F. McDermott et al. · Journal of Clinical Oncology · 2014 · 1.1K citations · Full text

Medicine, Immunology, Oncology +17

Phase IIB Multicenter Trial of Vorinostat in Patients With Persistent, Progressive, or Treatment Refractory Cutaneous T-Cell Lymphoma

Elise A. Olsen, Youn H. Kim, Timothy M. Kuzel et al. · Journal of Clinical Oncology · 2007 · 1K citations

Pharmacy, Oncology, Pharmacotherapy +16

gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma

Douglas J. Schwartzentruber, David H. Lawson, Jon Richards et al. · New England Journal of Medicine · 2011 · 888 citations

Medicine, Immunology, Oncology +14

Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial

Naomi B. Haas, Judith Manola, Robert G. Uzzo et al. · The Lancet · 2016 · 638 citations

Medicine, Oncology, Pharmacology +14

Pivotal Phase III Trial of Two Dose Levels of Denileukin Diftitox for the Treatment of Cutaneous T-Cell Lymphoma

Elise A. Olsen, Madeleine Duvic, Arthur E. Frankel et al. · Journal of Clinical Oncology · 2001 · 610 citations

Medicine, Oncology, Pharmacology +17